Companies /Healthcare

Biogen Inc

NASDAQ: BIIB Drug Manufacturers - General
$221.50
â–² $0.43 (+0.19%) today
Markets closed · 7:18am ET

BIIB Coverage

Page 40
7:54am ET
Investing

Pre-Market Stock News (January 28, 2008)

Alliance Data Systems (ADS) was informed by Blackstone that conditions likely won’t be satisfied to complete the merger; stock trading down close to 40%.American Express (AXP) reports earnings today with estimates at…

Douglas A. McIntyre
8:32am ET
Investing

Top Pre-Market Stock News (January 7, 2008)

Below is a snapshot of some of the key impact news affecting stocks in pre-market trading this Monday, January 7, 2008: AllianceBernstein (AB) noted as a hidden gem in Barron’s cover story.…

Douglas A. McIntyre
4:44pm ET
Health and Healthcare

Biogen Loses BAIT SHOP Status, Officially & Again (BIIB, PFE)

Biogen-Iden (NASDAQ:BIIB) is seeing its shares pummeled in after-hours trading.  The company didn’t have another biotech drug crisis though. Biogen had been under a corporate strategic review where it was evaluating strategic…

Douglas A. McIntyre
8:05am ET
Investing

Pre-Market Stock News (November 20, 2007)

Biogen Idec (BIIB) announced an alliance with Neurimmune Therapeutics to develop treatments for Alzheimer’s Disease.BJ’s Wholesale (BJ) $0.35 EPS vs $0.33 est.Blue Coat Systems (BCSI) $0.30 EPS vs $0.24 est.; sees next…

Douglas A. McIntyre
8:40am ET
Health and Healthcare

Biogen Idec (BIIB) Puts Itself On The Block

Biotech firm Biogen Idec (BIIB) has put itself on the block, another victim of shareholder activist by Carl Icahn. The company said that several firms had expressed interest. According to The Wall…

Douglas A. McIntyre
6:42am ET
Investing

Pre-Market Analyst Calls (October 2, 2007)

ACAD started as Hold at Citigroup.ALB raised to Neutral at Goldman Sachs.AMB raised to Buy at B of A.APD cut to Neutral at Goldman Sachs.BAC started as Buy at Goldman Sachs.BDN cut…

Douglas A. McIntyre
7:25am ET
Health and Healthcare

Amgen Set To Run (AMGN, JNJ, BIIB)

Amgen Inc. (NASDAQ:AMGN) is seeing shares trade up another 2% pre-market after yesterday’s decision where an FDA panel rejected a proposal to set a specific target for red blood-cell levels in kidney-failure…

Douglas A. McIntyre